MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Milestone Payment

    Contingent payment triggered by a defined event in a partnership, M&A, or financing.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Milestone payments - common in licensing deals and acquisitions - release capital upon defined regulatory (e.g., PMA approval), clinical (e.g., enrollment), or commercial (e.g., sales thresholds) milestones. In acquisitions these payments are often called earnouts or contingent consideration, and they bridge valuation gaps when buyer and seller disagree on the odds of approval or adoption. Milestones need precise definitions, such as which approval, in which market, by what date. Disputes often arise over whether the buyer made commercially reasonable efforts to reach the milestone after closing.
    What the regulation says
    While milestone payments are primarily a financial construct, regulatory approvals are frequently designated as milestones. For example, a payment might be contingent upon obtaining a 510(k) clearance or a Premarket Approval (PMA) from the FDA, or a CE Mark under the EU Medical Device Regulation (EU MDR). These regulatory achievements directly impact a MedTech product's market access and commercial viability, thus serving as critical junctures for financial disbursements in agreements.

    What this means in practice

    Deal value often hinges on milestone structure: heavy back-end milestones reduce upfront risk for the acquirer but defer founder/investor proceeds.

    Examples

    • A licensing agreement stipulates a $10 million payment to the licensor upon the FDA granting Premarket Approval (PMA) for the licensed Class III diagnostic device.
    • An acquisition deal includes a clause for an additional $5 million to the acquired company's founders once their novel robotic surgical system receives a CE Mark under the EU MDR, allowing it to be marketed in Europe.
    • A development contract specifies a payment upon successful submission of a 510(k) premarket notification to the FDA for a new medical imaging device, demonstrating progress toward market authorization.
    Common pitfalls
    • •Misinterpreting regulatory milestones can lead to significant financial and project timeline discrepancies.
    • •Failing to clearly define the exact regulatory event triggering a payment can result in disputes between parties.
    • •Overlooking the potential for regulatory delays to impact milestone payment schedules is a common mistake.
    • •Assuming regulatory submissions alone, rather than final approvals, constitute a payment milestone can create confusion.

    Frequently asked questions

    Regulatory milestones are tied to approvals or clearances from authorities like the FDA or a Notified Body, while clinical milestones relate to progress in human studies, such as patient enrollment completion or successful interim trial results.

    Cross-references

    Used by

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    4 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 4Trade press and expert commentary· 4
    Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01
    BIO·1PitchBook·1NVCA·1IFRS Foundation·1
    1. 1
      BIO Deal Database
      Tier 4 Verified
      BIObio.org
    2. 2
      PitchBook - MedTech Coverage
      Tier 4 Verified
      PitchBookpitchbook.com
    3. 3
      NVCA Model Documents
      Tier 4 Verified
      NVCAnvca.org
    4. 4
      IFRS 3: contingent acquisition consideration (accounting context)
      Tier 4 Verified
      IFRS Foundationifrs.org

    Inline markers like [1] jump to the matching reference above.